文献速递临床试验与 GCP基础与转化研究

PCI术后指导性抗血小板治疗与标准治疗的荟萃分析

Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
PubMed 文献 · Lancet · 2021-01-01

BACKGROUND: Whether guided selection of antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI) is effective in improving outcomes compared with standard antiplatelet therapy remains controversial.…

要点

  • 指导性治疗减少心血管死亡、心梗、支架血栓和卒中。
  • 升级策略减少缺血事件不增加出血,降级策略减少出血不损失疗效。

核心结论

  • 指导性抗血小板治疗改善复合及单项疗效终点,安全性良好,主要由轻微出血减少驱动。
  • 支持在PCI患者中使用血小板功能或基因检测优化抗血小板药物选择。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Cochrane、Embase和Web of Science(2020年8月20日至10月25日)。
  • 比较指导性抗血小板治疗(基于血小板功能或基因检测)与标准抗血小板治疗。
  • 采用随机效应或固定效应模型计算风险比(RR)及95%CI。

主要发现

  • 全因死亡和大出血风险两组无差异。
  • 升级策略显著减少缺血事件且不增加出血,降级策略显著减少出血且不损失疗效。

临床怎么用

  • PCI患者可考虑采用血小板功能或基因检测指导抗血小板药物选择以优化预后。
  • 根据缺血与出血风险选择升级或降级策略:高缺血风险者可能获益于升级,高出血风险者可能获益于降级。

局限性

  • 纳入研究包含观察性研究,可能存在混杂偏倚。
  • 不同指导策略(升级与降级)效果存在异质性,需个体化解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether guided selection of antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI) is effective in improving outcomes compared with standard antiplatelet therapy remains controversial. We assessed the safety and efficacy of guided versus standard selection of antiplatelet therapy in patients undergoing PCI. METHODS: For this systematic review and meta-analysis, from Aug 20 to Oct 25, 2020, we searched MEDLINE (via PubMed), Cochrane, Embase, and Web of Science databases for randomised controlled trials and observational studies published in any language that compared guided antiplatelet therapy, by means of platelet function testing or genetic testing, versus standard antiplatelet therapy in patients undergoing PCI. Two reviewers independently assessed study eligibility, extracted the data, and assessed risk of bias. Risk ratios (RRs) and 95% CIs were used with random-effects or fixed-effect models according to the estimated heterogeneity among studies assessed by the I2 index. Coprimary endpoints were trial-defined primary major adverse cardiovascular events and any bleeding. Key secondary endpoints were all-cause death, cardiovascular death, myocardial infarction, stroke, definite or probable stent thrombosis, and major and minor bleeding. This study is registered with PROSPERO (CRD42021215901). FINDINGS: 3656 potentially relevant articles were screened. Our analysis included 11 randomised controlled trials and three observational studies with data for 20 743 patients. Compared with standard therapy, guided selection of antiplatelet therapy was associated with a reduction in major adverse cardiovascular events (RR 0·78, 95% CI 0·63-0·95, p=0·015) and reduced bleeding, although not statistically significant (RR 0·88, 0·77-1·01, p=0·069). Cardiovascular death (RR 0·77, 95% CI 0·59-1·00, p=0·049), myocardial infarction (RR 0·76, 0·60-0·96, p=0·021), stent thrombosis (RR 0·64, 0·46-0·89, p=0·011), stroke (RR 0·66, 0·48-0·91, p=0·010), and minor bleeding (RR 0·78, 0·67-0·92, p=0·0030) were reduced with guided therapy compared with standard therapy. Risks of all-cause death and major bleeding did not differ between guided and standard approaches. Outcomes varied according to the strategy used, with an escalation approach associated with a significant reduction in ischaemic events without any trade-off in safety, and a de-escalation approach associated with a significant reduction in bleeding, without any trade-off in efficacy. INTERPRETATION: Guided selection of antiplatelet therapy improved both composite and individual efficacy outcomes with a favourable safety profile, driven by a reduction in minor bleeding, supporting the use of platelet function or genetic testing to optimise the choice of agent in patients undergoing PCI. FUNDING: None.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Galli M, Benenati S, Capodanno D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet. 2021. PMID: 33865495. doi:10.1016/S0140-6736(21)00533-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。